More migraine-free days in patients with an inadequate response to 2 or more prior preventive treatments¹*

Improvements were seen as early as week 1 and were sustained throughout the 3-month treatment period (exploratory endpoint)^1†

^†For all exploratory analyses, no determination of statistical significance can be made and no conclusions should be drawn.

Patients who achieved ≥50% reduction in monthly average migraine days¹

34% of patients achieved a ≥50% reduction of average monthly migraine days with either quarterly or monthly dosing vs 9% for placebo (P<0.0001) (secondary endpoint)¹

Results in patients with an inadequate response to anticonvulsants or neurotoxins (exploratory analysis)^‡

• 3.8 mean reduction from baseline in monthly average migraine days for both quarterly and monthly arms vs 1.0 for placebo in patients with previous anticonvulsant use²
• 2.7 and 3.2 mean reduction from baseline in monthly average migraine days for quarterly and monthly arms, respectively, vs 0.2 for placebo in patients who previously used neurotoxins²

^‡For all exploratory analyses, no determination of statistical significance can be made and no conclusions should be drawn.

Patients experienced a significant reduction in the monthly average number of days using migraine-specific acute headache medication (secondary endpoint)²

• Mean reduction of 3.7 days for quarterly dosing and 3.9 days for monthly dosing of migraine-specific acute headache medication use vs 0.6 days with placebo²